Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SUM159PT Pictilisib
1.0
pan PI3K
PI3K/mTOR
 0.5262 -0.00713
MDA-MB-134-VI ABT-737
0.001
Bcl2/XL
Misc
 0.9548 -0.00713
MDA-MB-134-VI Tivantinib
0.01
MET
RTK
 1.0707 -0.00712
MDA-MB-436 Trametinib
0.031623
MEK
MAPK/nRTK
 0.7645 -0.00712
PDXHCI002 Buparlisib
0.01
pan PI3K
PI3K/mTOR
 1.1174 -0.00711
MDA-MB-157 Bleomycin
0.0033333
Radiation
Misc
 0.9678 -0.00710
CAMA-1 Saracatinib
10.0
SRC
MAPK/nRTK
 0.7736 -0.00710
CAL-85-1 Palbociclib
1.0
CDK4/6
Cell cycle
 1.0849 -0.00708
PDXHCI002 Alpelisib
0.31623
PI3Ka
PI3K/mTOR
 0.9314 -0.00707
HCC1419 Dinaciclib
0.0031623
pan CDK
Cell cycle
 1.2758 -0.00707
CAL-85-1 Olaparib
0.01
PARP
Misc
 1.0245 -0.00706
HCC70 Palbociclib
0.0031623
CDK4/6
Cell cycle
 1.0888 -0.00706
HCC38 A-1210477
0.031623
Mcl-1
Misc
 0.9783 -0.00705
MCF 10A Trametinib
0.0031623
MEK
MAPK/nRTK
 0.5384 -0.00704
CAL-120 Cabozantinib
1.0
VEGFR2/MET
RTK
 0.9583 -0.00704
MDA-MB-361 Etoposide
0.01
Topo II
Chemotherapy
 0.9125 -0.00702
HCC38 Alpelisib
0.01
PI3Ka
PI3K/mTOR
 1.0893 -0.00702
PDX1328 Etoposide
0.031667
Topo II
Chemotherapy
 0.9924 -0.00700
MDA-MB-134-VI Tivantinib
0.001
MET
RTK
 1.1350 -0.00700
CAL-85-1 Ceritinib
0.031623
ALK
RTK
 0.9664 -0.00697
HCC1954 Ipatasertib
0.01
AKT
PI3K/mTOR
 1.0190 -0.00696
MCF 10A Pictilisib
0.31623
pan PI3K
PI3K/mTOR
 0.7565 -0.00695
HCC1806 Vorinostat
0.001
HDAC
Misc
 1.0136 -0.00693
PDX1258 ABT-737
0.001
Bcl2/XL
Misc
 1.0655 -0.00693
MCF 10A Palbociclib
0.031623
CDK4/6
Cell cycle
 0.8531 -0.00692